Promising new combo aims to tame childhood leukemia with less chemo

NCT ID NCT07152041

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This clinical trial is testing a new combination of drugs for children and teens with a specific type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study uses a targeted drug called olverembatinib along with immune therapy (blinatumomab) and another targeted drug (venetoclax) to try to kill leukemia cells more effectively while using less traditional chemotherapy. The goal is to see if this approach leads to better remission rates with fewer side effects. The trial plans to enroll 150 participants aged 1 month to 18 years who are newly diagnosed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olverembatinib (a targeted drug), blinatumomab (an immune therapy), and venetoclax (a targeted drug)
What this could lead to: If successful, this could offer a more effective and less toxic treatment option for children with Ph+ acute lymphoblastic leukemia, potentially improving remission rates and reducing side effects from chemotherapy.
What could go wrong: This is an early-phase 3 trial with a relatively small sample size (150 participants). The new combination may not prove superior to current treatments, and there are risks of serious side effects from the immune therapy and targeted drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PHILADELPHIA CHROMOSOME-POSITIVE (PH+) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult acute lymphoblastic leukemia B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) childhood acute lymphoblastic leukemia leukemia, acute lymphocytic, susceptibility to, 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHILDHOOD LEUKEMIA, ACUTE LYMPHOBLASTIC

Contacts and locations

Locations

Affiliated Hospital of Qingdao University
NOT_YET_RECRUITING

Qingdao, Shandong, China
Anhui Medical University Second Affiliated Hospita
NOT_YET_RECRUITING

Hefei, Anhui, China
Children's Hospital of Fudan University
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, China
Children's Hospital of Soochow University
NOT_YET_RECRUITING

Suzhou, Jiangsu, China
Chongqing Medical University Affiliated Children's Hospital
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, China
Fujian Medical University Union Hospital
NOT_YET_RECRUITING

Fuzhou, Fujian, China
Guangzhou Women and Children's Medical Center
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
Hong Kong Children's Hospital, The Chinese University of Hong Kong
NOT_YET_RECRUITING

Hong Kong, Hong Kong
Hunan Children's Hospital
NOT_YET_RECRUITING

Changsha, Hunan, China
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
RECRUITING

Tianjin, Tianjin Municipality, China
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, China
Jiangxi Provincial Children's Hospital
NOT_YET_RECRUITING

Nanchang, Jiangxi, China
Nanfang Hospital, Southern Medical University
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
Nanjing Children's Hospital Affiliated to Nanjing Medical University
NOT_YET_RECRUITING

Nanjin, Jiangsu, China
Qilu Hospital of Shandong University
NOT_YET_RECRUITING

Jinan, Shandong, China
Shanghai Children's Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, China
Shenzhen Children's Hospital
NOT_YET_RECRUITING

Shenzhen, Shenzhen, China
The Affiliated Hospital of Guizhou Medical University
NOT_YET_RECRUITING

Guiyang, Guizhou, China
The First Affiliated Hospital, Sun Yat-sen University
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
The Third Xiangya Hospital of the Central South University
NOT_YET_RECRUITING

Changsha, Hunan, China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITING

Wuhan, Hubei, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITING

Wuhan, Hubei, China
West China Second University Hospita
NOT_YET_RECRUITING

Chengdu, Sichuan, China
Wuhan Children's Hospital
NOT_YET_RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.